Prothena | PRTA - Current Assets


Prothena reported $339.2M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025